Sodium monofluorophosphate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1986
- First approval year
- 1986
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Sodium monofluorophosphate
- Molecular weight
- 143.95
- Structure (SMILES)
- O=P([O-])([O-])F.[Na+].[Na+]
- extra strength aim
- Extra-strength aim
- mono tridin
- Mono-tridin
- extra
- extra fine hydrofluoroalkane beclometasone dipropionate
- extra fine hydrofluoroalkane beclomethasone mdi
- extra-fine hydrofluoroalkane beclometasone dipropionate
- Extra-fine hydrofluoroalkane beclometasone dipropionate
- Extra-fine hydrofluoroalkane beclomethasone MDI
- Extra-fine hydrofluoroalkane-beclometasone dipropionate
- nsc 248
- NSC-248
- phosphorofluoridic acid disodium salt
- PHOSPHOROFLUORIDIC ACID, DISODIUM SALT
- sodium fluorophosphate
- Sodium fluorophosphate
- Sodium fluorophosphate [WHO-DD]
- sodium fluorophosphate who dd
- sodium monofluorophosphate
- Sodium monofluorophosphate
- Sodium Monofluorophosphate
- SODIUM MONOFLUOROPHOSPHATE [MART.]
- SODIUM MONOFLUOROPHOSPHATE [ORANGE BOOK]
- SODIUM MONOFLUOROPHOSPHATE [USP MONOGRAPH]
- SODIUM MONOFLUOROPHOSPHATE [USP-RS]
- sodium monofluorophosphate mart
- sodium monofluorophosphate orange book
- sodium monofluorophosphate usp monograph
And 1 more, listed on the interactive page.
- CAS registry numbers
- 10163-15-2
- ChEMBL ID
- CHEMBL1908359
- InChIKey
- BFDWBSRJQZPEEB-UHFFFAOYSA-L
- RxNorm IDs (RxCUI)
- 56501
- FDA ingredient codes (UNII)
- C810JCZ56Q
- A01AA02
- A12CD02
Sources for recorded values
- 24266
- 66524099
- Applicant
- CHESEBROUGH PONDS
- Approval date
- 6 Aug 1986
- Application number
- NDA019518
- First in class
- No
- Orphan designation
- No
- Availability
- discontinued
- United States (FDA)
- Approved
Administration routes
- topical
- Condition
- Periodontitis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000649
- Subject identifier
- D010518
- Condition
- Dental Caries
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003819
- Subject identifier
- D003731
- Condition
- Gingivitis
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002508
- Subject identifier
- D005891
- Condition
- Gingival Diseases
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002635
- Subject identifier
- D005882
- Condition
- Hypersensitivity
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005271
- Subject identifier
- D006967
- Condition identifier
- EFO_0000649
- Condition identifier
- EFO_0003819
- Condition identifier
- MONDO_0002508
- Condition identifier
- MONDO_0002508
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0002635
- Condition identifier
- MONDO_0002635
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005076
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005271
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005276
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0006722
- Highest recorded phase
- 1
- Event
- anaphylactic shock
- Reports
- 3
- Reporting signal score
- 8.08832
- Event
- blood amylase decreased
- Reports
- 1
- Reporting signal score
- 7.39303
- Event
- cardiac valve disease
- Reports
- 3
- Reporting signal score
- 13.6635
- Event
- cholecystitis
- Reports
- 2
- Reporting signal score
- 6.2962
- Event
- crest syndrome
- Reports
- 1
- Reporting signal score
- 6.49954
- Event
- cytokine release syndrome
- Reports
- 4
- Reporting signal score
- 15.8197
- Event
- dermatitis bullous
- Reports
- 3
- Reporting signal score
- 10.8822
- Event
- eyelid injury
- Reports
- 1
- Reporting signal score
- 7.19241
- Event
- fibrin d dimer increased
- Reports
- 2
- Reporting signal score
- 8.49008
- Event
- hip fracture
- Reports
- 3
- Reporting signal score
- 8.68149
- Event
- intercepted drug dispensing error
- Reports
- 2
- Reporting signal score
- 10.6961
- Event
- lacrimal structure injury
- Reports
- 1
- Reporting signal score
- 10.6887
- Event
- lipase increased
- Reports
- 2
- Reporting signal score
- 6.30998
- Event
- liver injury
- Reports
- 3
- Reporting signal score
- 9.09432
- Event
- oesophageal dilatation
- Reports
- 1
- Reporting signal score
- 6.05477
- Event
- oral discomfort
- Reports
- 2
- Reporting signal score
- 7.25279
- Event
- oral soft tissue disorder
- Reports
- 1
- Reporting signal score
- 5.78449
- Event
- pancreatitis acute
- Reports
- 3
- Reporting signal score
- 7.63761
- Event
- pancytopenia
- Reports
- 3
- Reporting signal score
- 5.65028
- Event
- pharmaceutical product counterfeit
- Reports
- 1
- Reporting signal score
- 6.70011
- Event
- sudden cardiac death
- Reports
- 1
- Reporting signal score
- 6.35854
- Event
- upper gastrointestinal haemorrhage
- Reports
- 3
- Reporting signal score
- 9.60234
- NCT00762528
- NCT00941668
- NCT04123665
- NCT01005966
- NCT01831817
- Dose
- Pea sized amount
- How often
- Twice daily
- Supervise child's brushing and rinsing
- Use only as directed by dentist or physician
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- Yes
- Heavy atoms
- 7
- Molecular formula
- FNa2O3P
- Monoisotopic mass
- 143.93644758
- Natural product
- No
- Recorded assays
- 14
- Active assays
- 0
Related records
Trials (34)
- A Bleeding-Model Clinical Study
- A Clinical Study Conducted in the Bangkok, Thailand Area, to Investigate the Clinical Efficacy of a New Toothpaste
- A Clinical Study to Assess the Effects of Various Dentifrice Technologies on Dentinal Hypersensitivity
- A Clinical Study to Assess the Gingivitis and Plaque Effects of Various Dentifrices
- A Clinical Study to Assess the Gingivitis Effects of Various Dentifrices
- A Phase 3 Clinical Study Investigating the Gingivitis Efficacy of a Test Dentifrice Containing Stannous Fluoride
- A Three Month Bleeding-Model Clinical Study
- Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice
- Assessing Gingivitis and Plaque From a Marketed Toothpaste
- Assessing Gingivitis of 3 Different Dentifrices Compared to a Negative Control.
- Brief Title: a Clinical Study to Assess Gingivitis
- Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity
- Clinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in a Population With High Plaque/Low Gingivitis and High Plaque/High Gingivitis
- Compare Anti-inflammatory Dentifrices
- Dentin Hypersensitivity Reduction Efficacy Clinical
- Effectiveness of Arginin and Potassium Nitrate Dentifrices in Dentin Hypersensitivity Therapy
- Efficacy of a Stannous Fluoride Toothpaste, Cetylpyridinium Chloride Mouthwash, and Battery Toothbrush Regimen in Reducing Established Dental Plaque and Gingivitis.
- Efficacy of Manual Toothbrushes in Removing Tooth Stains
- Efficacy of Toothpaste Containing 0.454% Stannous Fluoride as Compared to a Regular Fluoride Toothpaste Containing 0.76% Sodium Monofluorophosphate in Controlling Supragingival Calculus Formation Over a 12-week Period.
- Evaluate Inflammation Caused by Gingivitis in Adults
Approved for (4)
- Dental caries
- Gingivitis
- Periodontal disorder
- Periodontitis
In development for (2)
- Allergic disease Phase 2
- Dental fluorosis Phase 1